NVO vs. AZN
Compare and contrast key facts about Novo Nordisk A/S (NVO) and AstraZeneca PLC (AZN).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NVO or AZN.
Correlation
The correlation between NVO and AZN is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NVO vs. AZN - Performance Comparison
Key characteristics
NVO:
-0.86
AZN:
1.17
NVO:
-1.11
AZN:
1.60
NVO:
0.85
AZN:
1.22
NVO:
-0.69
AZN:
0.86
NVO:
-1.55
AZN:
1.80
NVO:
20.97%
AZN:
13.26%
NVO:
37.76%
AZN:
20.27%
NVO:
-71.32%
AZN:
-48.94%
NVO:
-43.75%
AZN:
-14.63%
Fundamentals
NVO:
$355.35B
AZN:
$231.90B
NVO:
$3.18
AZN:
$2.25
NVO:
25.89
AZN:
33.24
NVO:
1.13
AZN:
0.86
NVO:
$290.40B
AZN:
$54.07B
NVO:
$245.88B
AZN:
$43.87B
NVO:
$148.56B
AZN:
$17.22B
Returns By Period
In the year-to-date period, NVO achieves a -4.29% return, which is significantly lower than AZN's 14.16% return. Over the past 10 years, NVO has outperformed AZN with an annualized return of 15.56%, while AZN has yielded a comparatively lower 11.40% annualized return.
NVO
-4.29%
4.63%
-39.38%
-32.88%
23.04%
15.56%
AZN
14.16%
12.31%
-12.13%
18.90%
11.57%
11.40%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NVO vs. AZN — Risk-Adjusted Performance Rank
NVO
AZN
NVO vs. AZN - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NVO vs. AZN - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 1.75%, less than AZN's 1.99% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 1.75% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
AZN AstraZeneca PLC | 1.99% | 2.27% | 2.15% | 2.14% | 2.40% | 2.80% | 2.81% | 3.61% | 3.95% | 5.01% | 4.06% | 3.98% |
Drawdowns
NVO vs. AZN - Drawdown Comparison
The maximum NVO drawdown since its inception was -71.32%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for NVO and AZN. For additional features, visit the drawdowns tool.
Volatility
NVO vs. AZN - Volatility Comparison
Novo Nordisk A/S (NVO) has a higher volatility of 14.49% compared to AstraZeneca PLC (AZN) at 5.71%. This indicates that NVO's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NVO vs. AZN - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities